|
|
3865 Niagara Lane N.
Minneapolis, MN 55446 USA USA
phone:612-695-2465
fax:0
|
|
| Symbol |
Private |
| Founded |
2008 |
| Employees |
|
|
|
| www.innovamedicaldesign.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Alleviates needle pain related to venipuncture, injection, vaccination and lancet procedures. |
|
| Management |
| Tim O'Malley, CEO/Chair; Mel Vallero, M.D./Medical Director/Inventor; John Buske, CFO; |
| |
|
|
| |
|
| Keywords |
| pain, needle, lancet, injection, shot, noninvasive, venous access, venipuncture, blood draw, blood sample, IV, intravenous, vaccination, syringe, cutaneous, neurostimulation, neuromodulation, disposable, OTC, bandage, electrode, diabetes, drug administration, hospital, clinic, patient, pediatric, medical device, device, TENS, vibration, nerve, stimulation, productivity, compliance |
|
|
|
| Description |
Innova is a development stage company that has designed an effective and pragmatic solution to alleviate needle pain associated with blood draws, IV starts, injections, vaccinations and lancet piercing. Prototypes have been produced and successfully tested in 2009. New product development is underway to address needle and lancet pain for diabetic patients. Innova is located in Minneapolis, MN.
Innova Medical Design alleviates needle pain related to acute venipuncture, intramuscular injection and vaccination procedures. Besides altering the most universal pain experiences incurred from infancy through adulthood, Innova's pain relief is immediate, involves no drugs, integrates seamlessly with existing procedures and can be individually tailored to each patient's comfort level. Staff resources to support venipuncture and injection procedures are reduced, throughput times shortened, patient compliance improved and staff motivation positively impacted. New product development has begun in diabetes to relieve daily needle and lancet pain caused by insulin injections and blood sampling. |
|
| Products / Services |
Innova's initial product system is comprised of a disposable electrode patch and small detachable neurostimulation device. The patches and stimulation devices are configured for use in: a) venipuncture procedures such as blood draws and IV starts and, b) intramuscular injections and vaccinations. Through low level cutaneous TENS stimulation and vibration, needle pain is masked and blocked. Levels of stimulation can be adjusted to each patient's needs. The electrode patches also serve the dual function of a bandage after the procedure.
|
|
| Technology / Differentiation |
Innova's technical solution is superior to competitive alternatives as it is:
-effective immediately with no waiting period
-individually adjustable to each patient's needs
-integrates with existing procedures, no extra time
-involves no drugs or creams
-simple to use by staff
-reward 'sticker' incentive for pediatric patients
-reduces demands on staff resources, saves time
-increases compliance and patient satisfaction |
|
| Market / Customers |
There are over 1.3 billion venipuncture procedures in the USA each year and over 24 billion syringes are used annually for injections. Innova's customers include all healthcare providers in settings that perform venipuncture procedures, injections and vaccinations. Hospitals, clinics and reference laboratories are primary Innova client targets. Innova is also developing an OTC product configuration for the pediatric injection and vaccination market. Diabetic product systems under development target people with diabetes who perform daily blood tests and/or inject insulin.
|
|
| Status |
| Prototypes for venipuncture and injection models have been successfully developed and tested. Development is now in the final stages with transfer to manufacturing for its venipuncture product system. Patent applications and CIP have been filed for all product concepts and iterations. Regulatory plans and CRO are established and marketing strategies defined. The company is seeking initial outside funding. Final product design, transfer to manufacturing and FDA approval of the venipuncture system can be completed within 12 months. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members